An investigation published this week describes a growing group of oncologists, researchers and patients arguing that some cancer drugs are approved and prescribed at doses higher than patients need, and that the extra dose buys toxicity rather than benefit.
The reporting, published by KFF Health News and carried by CNN, opens with Northwestern University economist Chuck Manski, who received monthly nivolumab infusions for advanced melanoma in 2022. He said the drug ruined his thyroid gland, leaving him on medication for life, and caused severe dryness in his eyes, lips, and mouth. The protocol called for a full year. He stopped at six months after concluding from the medical literature that the treatment had likely done what it could.
